Minimally invasive screening methods offer a more accessible, cost-effective way to detect Barrett’s esophagus early and help prevent esophageal cancer.

Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that ...

Steve Dorsey has issued a stark warning for his fellow firefighters to check on one common undetected cancer symptom.

Southeast Weld Fire Chief Tom Beach lost both his parents to cancer in the same year. Cancer’s impact on Beach moved him to prioritize preventative screenings for his firefighting team. While they ...

Esophageal cancer is an aggressive, deadly cancer often caught in advanced stages. The likelihood of surviving for five years ...

PAVmed’s future outlook is optimistic, with expectations for Medicare coverage for its EsoGuard product "imminently." The partnership with Ohio State University is set to enroll 1,000 patients in its ...

Revenue from EsoGuard tests reached $0.8 million in Q1 2025, with a test volume of 3,034. While the company continues to await a response from the MolDX program regarding Medicare coverage, ...

CEO Lishan Aklog stated that Lucid Diagnostics is “better positioned than ever to capitalize on EsoGuard’s really huge clinical and market opportunity,” emphasizing recent progress including ...

Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash ...

Its subsidiary, Lucid Diagnostics Inc. (NASDAQ: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard ® Esophageal DNA Test and EsoCheck ...